World J Urol (2017) 35:1159–1160 DOI 10.1007/s00345-017-2041-5 EDITORIAL 1 2 Peter Albers · Carsten Bokemeyer Received: 18 April 2017 / Accepted: 19 April 2017 / Published online: 16 May 2017 © Springer-Verlag Berlin Heidelberg 2017 In spite of an increasing incidence in most of the Northern of patients that cannot undergo complete resections . industrialized countries in Europe germ cell cancer remains Salvage high-dose chemotherapy regimens are currently a rare disease. Diagnostic and management strategies have standard of care to treat recurrent disease. Exact classifica - been published numerously, but still there remain prob- tion of patients using the Lorch–Beyer classification system lems to be solved. Oldenburg and Dieckmann balanced the for recurrences and a large body of experience is necessary debate of pros and cons of a contralateral biopsy. Bottom to achieve optimal results with these potentially toxic regi- line is that a contralateral biopsy is the only way to early mens . More and more data demand this salvage treat- detect cancer within the “testicular dysgenesis syndrome” ment to be regionalized in centers with high experience. which has been molecularly identified over the last years This exactly is true as well for the second component of by
World Journal of Urology – Springer Journals
Published: May 16, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera